Alpha Teknova, Inc. (TKNO) stock

TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30150% above fair value

$8.29−0.32 (-3.77%)

Close on Nov 12, 2026Market cap $445.34MP/E –Yield –

Alpha Teknova EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Alpha Teknova's EV/EBITDA was 260.4× on Oct 29, 2021.

Period	Period end	Value	Change (pts)
2021	Oct 29, 2021	260.4×	–

Parsed from the XBRL in Alpha Teknova's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TKNO.

Revenue growth15.4% · median 12.5%

Gross margin36.4% · median 53.1%

Operating margin-32.7% · median -114.1%

Net margin-34.8% · median -162.3%

Advertisement
300 × 250

See a number that looks wrong?